A Phase 3 interventional study of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg and Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg in Alzheimer´s Disease, sponsored by Baxalta now part of Shire. Completed at 41 sites in 2 countries. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 244th largest by enrollment of the 1,611 interventional ones that give a count, is one of 54 that started in 2008, is one of 188 in phase 3, and was the 302nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 50 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,942 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 54 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 390 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,611 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,942 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Takeda has 7 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,942 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).
Study visits: Each participant will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). The first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. Each participant must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
This study's enrollment of 390 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted before Baxalta became part of Takeda.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Main Inclusion Criteria:
Main Exclusion Criteria (Reasons why it might not be appropriate to participate):
Medical issues that might increase the risk of treatment with IGIV, 10%, such as:
Medical issues that might interfere with the evaluation of the treatment of dementia or might make dementia worse, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
0.25% human albumin solution infused at 4 mL/kg/2weeks
Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg
0.25% human albumin solution infused at 2 mL/kg/2weeks
Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg
Drug page: Immunoglobulins, Intravenous
400 mg/kg bodyweight every 2 weeks for 70 weeks
Also known as: Gammagard Liquid, KIOVIG
Drug page: Immunoglobulins, Intravenous
200 mg/kg bodyweight every 2 weeks for 70 weeks
Also known as: Gammagard Liquid
Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
Time frame: Baseline & 18 Months
Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
Time frame: Baseline & 9 months
Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
Time frame: Baseline & 9 Months
Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment
The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse
Time frame: Baseline & 9 Months
Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment
The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse
Time frame: Baseline & 18 Months
Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination
The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment
The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward
This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward
This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency
In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as 'acts,' 'acted,' 'acting'). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution
WAIS-R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency
In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category "animals" as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A
This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B
This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.
Time frame: Baseline & 18 months
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test
In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to 'ten after eleven.' Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).
Time frame: Baseline & 18 months
Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class
Time frame: Throughout the study period, approximately 4 years
Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class
Time frame: Throughout the study period, approximately 4 years
Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class
Related and unrelated non-SAEs
Time frame: Throughout the study period, approximately 4 years
Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class
Related and unrelated SAEs
Time frame: Throughout the study period, approximately 4 years
Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)
Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)
Time frame: During or within 72 hours of completion of an infusion
Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)
Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered
Time frame: Throughout the study period, approximately 4 years
Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)
Time frame: Throughout each infusion period
Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits
Time frame: Throughout the study period, approximately 4 years
Number of Participants Experiencing a Clinically Significant Rash
Participants requiring systemic therapy or discontinuation from further treatment
Time frame: Throughout the study period, approximately 4 years
Recruitment was conducted in the U.S., and Canada, at 45 study sites. The first participant was enrolled in December 2008.
| Milestone | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 4 mL/kg | Placebo 2 mL/kg |
|---|---|---|---|---|
| Started | 127 | 135 | 58 | 63 |
| Completed | 104 | 102 | 49 | 47 |
| Not completed | 23 | 33 | 9 | 16 |
| Withdrew: Adverse event | 5 | 14 | 4 | 3 |
| Withdrew: Withdrawal by subject | 5 | 4 | 2 | 2 |
| Withdrew: Death | 1 | 3 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Unwilling or unable to participate | 4 | 6 | 2 | 4 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Requires a prohibited medication | 1 | 0 | 0 | 0 |
| Withdrew: Safety risk | 1 | 1 | 0 | 1 |
| Withdrew: Study partner unwilling or unable | 3 | 2 | 1 | 1 |
| Withdrew: Participant's health declined | 0 | 0 | 0 | 1 |
| Withdrew: Caregiver to pursue other treatment | 0 | 1 | 0 | 0 |
| Withdrew: Moving out of state | 0 | 0 | 0 | 1 |
| Withdrew: Declined move to another study site | 1 | 0 | 0 | 0 |
| Withdrew: Change in living situation | 0 | 0 | 0 | 1 |
| Withdrew: Study partner decision | 0 | 0 | 0 | 1 |
| Withdrew: Admitted to long term nursing care | 0 | 1 | 0 | 0 |
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) | 7.4 ± 7.95 | 8.9 ± 8.20 | 8.4 ± 9.37 |
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) | -11.4 ± 10.49 | -12.4 ± 11.41 | -11.4 ± 12.19 |
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) | 2.7 ± 5.20 | 4.5 ± 6.16 | 3.5 ± 6.44 |
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) | -5.4 ± 7.03 | -6.1 ± 8.13 | -5.8 ± 8.32 |
The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Month 9: Very much better (1) | 0 | 0 | 0 |
| Month 9: Much better (2) | 2 | 1 | 1 |
| Month 9: A little better (3) | 7 | 3 | 7 |
| Month 9: Same (4) | 33 | 33 | 36 |
| Month 9: A little worse (5) | 52 | 56 | 48 |
| Month 9: Much worse (6) | 19 | 18 | 12 |
| Month 9: Very much worse (7) | 1 | 3 | 0 |
The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Month 18: Very much better (1) | 0 | 0 | 0 |
| Month 18: Much better (2) | 1 | 2 | 1 |
| Month 18: A little better (3) | 6 | 1 | 3 |
| Month 18: Same (4) | 15 | 15 | 16 |
| Month 18: A little worse (5) | 44 | 43 | 36 |
| Month 18: Much worse (6) | 32 | 33 | 32 |
| Month 18: Very much worse (7) | 7 | 7 | 4 |
The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination | -12.1 ± 13.12 | -15.3 ± 12.76 | -13.5 ± 10.95 |
The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment | 3.7 ± 12.93 | 4.9 ± 13.30 | 2.4 ± 10.77 |
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response | -0.5 ± 5.34 | -0.7 ± 4.40 | -1.5 ± 5.20 |
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response | -3.0 ± 4.97 | -2.5 ± 5.17 | -1.6 ± 5.12 |
This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.
| correct responses | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward | -0.8 ± 2.00 | -1.2 ± 2.21 | -1.1 ± 1.81 |
This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.
| correct responses | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward | -0.8 ± 1.95 | -1.2 ± 1.88 | -1.2 ± 1.79 |
In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as 'acts,' 'acted,' 'acting'). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
| correct responses | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency | -4.7 ± 8.60 | -7.4 ± 9.00 | -6.3 ± 8.17 |
WAIS-R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
| correct responses | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution | -6.8 ± 10.61 | -7.7 ± 9.67 | -6.2 ± 7.34 |
In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category "animals" as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.
| correct responses | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency | -2.8 ± 4.06 | -2.2 ± 6.84 | -2.7 ± 3.82 |
This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.
| seconds | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A | 21.6 ± 36.93 | 20.5 ± 30.61 | 21.3 ± 35.50 |
This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.
| seconds | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B | 13.0 ± 60.49 | 28.4 ± 65.01 | 31.9 ± 66.32 |
In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to 'ten after eleven.' Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).
| Scores on a scale | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test | -0.7 ± 1.27 | -0.7 ± 1.15 | -0.6 ± 1.17 |
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Blood and Lymphatic System Disorders | 7 | 2 | 1 |
| Cardiac Disorders | 1 | 0 | 4 |
| Eye Disorders | 1 | 1 | 0 |
| Gastrointestinal Disorders | 10 | 13 | 7 |
| General Disorders & Administration Site Conditions | 22 | 32 | 13 |
| Immune System Disorders | 0 | 1 | 0 |
| Infections and Infestations | 1 | 1 | 1 |
| Injury, Poisoning, and Procedural Complications | 5 | 1 | 0 |
| Investigations | 15 | 16 | 13 |
| Metabolism and Nutrition Disorders | 0 | 1 | 0 |
| Musculoskeletal and Connective Tissue Disorders | 7 | 5 | 0 |
| Nervous System Disorders | 33 | 34 | 24 |
| Psychiatric Disorders | 5 | 6 | 2 |
| Reproductive System and Breast Disorders | 0 | 1 | 0 |
| Respiratory, Thoracic and Mediastinal Disorders | 3 | 4 | 4 |
| Skin and Subcutaneous Tissue Disorders | 26 | 20 | 9 |
| Vascular Disorders | 10 | 18 | 17 |
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Cardiac Disorders | 1 | 0 | 1 |
| General Disorders & Administration Site Conditions | 0 | 0 | 1 |
| Immune System Disorders | 0 | 1 | 0 |
| Investigations | 0 | 2 | 0 |
| Nervous System Disorders | 1 | 2 | 0 |
| Psychiatric Disorders | 0 | 1 | 0 |
| Respiratory, Thoracic and Mediastinal Disorders | 0 | 1 | 1 |
| Vascular Disorders | 0 | 0 | 2 |
Related and unrelated non-SAEs
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Blood and Lymphatic System Disorders | 13 | 7 | 5 |
| Cardiac Disorders | 3 | 11 | 15 |
| Ear and Labyrinth Disorders | 4 | 3 | 5 |
| Endocrine Disorders | 1 | 0 | 1 |
| Eye Disorders | 14 | 5 | 9 |
| Gastrointestinal Disorders | 47 | 51 | 36 |
| General Disorders & Administration Site Conditions | 57 | 66 | 52 |
| Immune System Disorders | 1 | 7 | 3 |
| Infections and Infestations | 40 | 46 | 57 |
| Injury, Poisoning, and Procedural Complications | 36 | 37 | 50 |
| Investigations | 37 | 48 | 30 |
| Metabolism and Nutrition Disorders | 14 | 15 | 16 |
| Musculoskeletal and Connective Tissue Disorders | 40 | 44 | 27 |
| Neoplasms, Benign, Malignant and Unspecified | 8 | 8 | 13 |
| Nervous System Disorders | 63 | 73 | 53 |
| Psychiatric Disorders | 41 | 49 | 49 |
| Renal and Urinary Disorders | 13 | 16 | 12 |
| Reproductive System and Breast Disorders | 5 | 4 | 3 |
| Respiratory, Thoracic and Mediastinal Disorders | 23 | 35 | 23 |
| Skin and Subcutaneous Tissue Disorders | 49 | 52 | 31 |
| Social Circumstances | 0 | 1 | 0 |
| Surgical and Medical Procedures | 8 | 6 | 8 |
| Vascular Disorders | 22 | 30 | 31 |
Related and unrelated SAEs
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Blood and Lymphatic System Disorders | 2 | 0 | 1 |
| Cardiac Disorders | 5 | 3 | 3 |
| Ear and Labyrinth Disorders | 1 | 0 | 0 |
| Gastrointestinal Disorders | 5 | 1 | 1 |
| General Disorders & Administration Site Conditions | 2 | 4 | 2 |
| Hepatobiliary Disorders | 0 | 1 | 1 |
| Immune System Disorders | 0 | 1 | 0 |
| Infections and Infestations | 2 | 2 | 4 |
| Injury, Poisoning, and Procedural Complications | 3 | 2 | 2 |
| Investigations | 1 | 2 | 1 |
| Metabolism and Nutrition Disorders | 1 | 1 | 2 |
| Musculoskeletal and Connective Tissue Disorders | 2 | 3 | 0 |
| Neoplasms, Benign, Malignant and Unspecified | 0 | 3 | 3 |
| Nervous System Disorders | 3 | 6 | 5 |
| Psychiatric Disorders | 2 | 4 | 3 |
| Renal and Urinary Disorders | 0 | 1 | 1 |
| Respiratory, Thoracic and Mediastinal Disorders | 1 | 2 | 3 |
| Surgical and Medical Procedures | 0 | 1 | 1 |
| Vascular Disorders | 4 | 0 | 4 |
Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)
| Infusions | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs) | 396 | 467 | 349 |
Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered
| Infusions | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs) | 225 | 265 | 172 |
| Adverse events | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE) | 48 | 28 | 36 |
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits | 31 | 24 | 16 |
Participants requiring systemic therapy or discontinuation from further treatment
| participants | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Rash requiring discontinuation from treatment | 3 | 2 | 0 |
| Rash requiring systemic therapy | 19 | 16 | 8 |
Collected over Throughout the study period of approximately 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV, 10% 400mg/kg | — | 21/127 (16.5%) | 112/127 (88.2%) |
| IGIV, 10% 200mg/kg | — | 32/135 (23.7%) | 118/135 (87.4%) |
| Placebo 2 mL/kg or 4 mL/kg | — | 26/121 (21.5%) | 103/121 (85.1%) |
| Event | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| Urinary Tract InfectionInfections and infestations | 1/127 | 1/135 | 3/121 |
| Deep Vein ThrombosisVascular disorders | 1/127 | 0/135 | 3/121 |
| SyncopeNervous system disorders | 0/127 | 3/135 | 2/121 |
| PyrexiaGeneral disorders | 0/127 | 0/135 | 2/121 |
| DehydrationMetabolism and nutrition disorders | 1/127 | 0/135 | 2/121 |
| Lung Neoplasm MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/127 | 1/135 | 2/121 |
| AgitationPsychiatric disorders | 1/127 | 0/135 | 2/121 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/127 | 1/135 | 2/121 |
| Microcytic AnaemiaBlood and lymphatic system disorders | 2/127 | 0/135 | 0/121 |
| Coronary Artery DiseaseCardiac disorders | 2/127 | 0/135 | 0/121 |
| Event | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 2 mL/kg or 4 mL/kg |
|---|---|---|---|
| HeadacheNervous system disorders | 29/127 | 34/135 | 22/121 |
| FallInjury, poisoning and procedural complications | 14/127 | 16/135 | 23/121 |
| Infusion Site ExtravasationGeneral disorders | 23/127 | 15/135 | 21/121 |
| RashSkin and subcutaneous tissue disorders | 21/127 | 19/135 | 6/121 |
| DepressionPsychiatric disorders | 14/127 | 16/135 | 19/121 |
| Blood Pressure IncreasedInvestigations | 19/127 | 12/135 | 9/121 |
| DiarrhoeaGastrointestinal disorders | 18/127 | 19/135 | 15/121 |
| HypertensionVascular disorders | 14/127 | 18/135 | 11/121 |
| NauseaGastrointestinal disorders | 16/127 | 11/135 | 10/121 |
| DizzinessNervous system disorders | 16/127 | 13/135 | 12/121 |
| Age, Continuous(years) | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 4 mL/kg | Placebo 2 mL/kg | Total |
|---|---|---|---|---|---|
| Mean | 70.5 ± 9.6 | 70.1 ± 8.3 | 70.3 ± 9.7 | 70.1 ± 10.3 | 70.3 ± 9.3 |
| Sex: Female, Male(Participants) | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 4 mL/kg | Placebo 2 mL/kg | Total |
|---|---|---|---|---|---|
| Female | 69 | 74 | 33 | 33 | 209 |
| Male | 58 | 61 | 25 | 30 | 174 |
| Region of Enrollment(Participants) | IGIV, 10% 400mg/kg | IGIV, 10% 200mg/kg | Placebo 4 mL/kg | Placebo 2 mL/kg | Total |
|---|---|---|---|---|---|
| United States | 117 | 127 | 56 | 58 | 358 |
| Canada | 10 | 8 | 2 | 5 | 25 |
Ran from Dec 2008 to primary completion in Dec 2012, 47 months.
Results were first posted in Oct 2014, 1 year 10 months after primary completion.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 47 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous